CP
AUPH icon

Castleview Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Castleview Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-70
Closed -$302 – 671
2022
Q4 		$302 Buy
+70
New +$406 ﹤0.01% 602

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Castleview Partners's AUPH Position: Q1 2023 in Review

Castleview Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2023, closing a stake of 70 shares — an estimated $302 sold.

Castleview Partners first reported a position in AUPH in Q4 2022 and held it in 1 quarter. The position peaked at $302 in Q4 2022. 186 funds tracked by Wall St. Rank hold AUPH as of Q1 2023.

  • Castleview Partners reported no remaining Aurinia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Castleview Partners sold 70 Aurinia Pharmaceuticals shares in Q1 2023, an estimated $302.
  • Castleview Partners first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Castleview Partners's Aurinia Pharmaceuticals position peaked at $302 in Q4 2022.
  • 186 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.